Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05828979
Other study ID # CIP CCH2211240956
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2, 2023
Est. completion date November 2025

Study information

Verified date September 2023
Source UroMems SAS
Contact Caroline Soufflet
Phone +33480420240
Email caroline.soufflet@uromems.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter in women


Description:

This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive) in women.


Recruitment information / eligibility

Status Recruiting
Enrollment 6
Est. completion date November 2025
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged >18 years old - Female patient - Cognitively able and willing to sign an informed consent - Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months - Use of medically acceptable contraception, if of childbearing potential - Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints - Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator - Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator - Life expectancy = 5 years as assessed by the investigator - Affiliated with an appropriate social security system - Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, ACT, etc. (excluding other AUS devices) - Negative urine culture prior to the procedure - Urinary incontinence assessed by investigator with at least = 50 g in 24-hour pad-weight tests - Clinically insignificant post-void residual (PVR) urine defined as < 50 ml and/or no greater than 10% of the voided volume - Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary Exclusion Criteria: - Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months - Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing her from giving her consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn her consent) - Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions - Pregnant patient, or patient planning pregnancy during the study duration - Patient presenting one or several contraindications of the device - Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes - Known allergy to UroMems eAUS implantable components - History of pelvic irradiation (external beam therapy or brachytherapy) - Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of >12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of >9% (75 mmol/mol) over the preceding 3 months - History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value >70 - Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured - Previous AUS implant - Currently has another Active Implantable Medical Device (AIMD) implanted - Urge incontinence, mixed incontinence (MI) with a predominant urgency component - Overflow urinary incontinence - Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods - Abnormal or poor bladder compliance defined as being <30 ml/ cm H2O - Bladder neck or urethral stricture that may require any long-term instrumental treatment

Study Design


Intervention

Device:
UroMems artificial urinary sphincter
Implantation of the device

Locations

Country Name City State
France CHU Nantes Nantes
France Groupe Hospitalier Pitié-Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
UroMems SAS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of explants and revisions at 6 months after device activation Rate of explants and revisions 6 months after device activation
Primary Rate of device activation successes Rate of device activation successes 5 weeks after device implantation
Secondary Number of subjects with 50% reduction or greater in 24-hour pad weight test Number of subjects with 50% reduction or greater in 24-hour pad weight test 90, 185 and 365 days after activation
Secondary Number of subjects with 75% reduction or greater in 24-hour pad weight test Number of subjects with 75% reduction or greater in 24-hour pad weight test 90, 185 and 365 days after activation
Secondary 3-day bladder diary Bladder diary will be filled in during 3 consecutive days 90, 185 and 365 days after activation
Secondary General quality of life questionnaire General quality of life questionnaire 90, 185 and 365 days after activation
Secondary Disease specific questionnaire (level of incontinence) Disease specific questionnaire (level of incontinence) 90, 185 and 365 days after activation
Secondary Disease specific questionnaire (symptoms and quality of life) Disease specific questionnaire (symptoms and quality of life) 90, 185 and 365 days after activation
Secondary Disease specific questionnaire (sexual activity) Disease specific questionnaire (sexual activity) 90, 185 and 365 days after activation
Secondary Disease specific questionnaire (quality of life) Disease specific questionnaire (quality of life) 90, 185 and 365 days after activation
Secondary Disease specific questionnaire (type of incontinence) Disease specific questionnaire (type of incontinence) 90, 185 and 365 days after activation
Secondary Post void residuals Post void residuals will be measured to assess the bladder function Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation
Secondary Patient satisfaction Patient satisfaction questionnaire 5 weeks after device implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation
Secondary Physician satisfaction questionnaire Questionnaire to assess the physician satisfaction regarding the procedure and the device Within 45 days after baseline (device implantation), 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation
Secondary Rate of adverse events All categories: serious/not serious events and device- and procedure-related effects Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation
See also
  Status Clinical Trial Phase
Completed NCT06136975 - Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
Not yet recruiting NCT04390204 - Evaluation of the Effect of a Postural Reflex Rehabilitation Program on a Foam Surface on Stress Urinary Incontinence in Women N/A
Enrolling by invitation NCT05404386 - Effect of Mobile Application on Urinary Incontinence N/A
Completed NCT05096936 - Pilates Method and/or Photobiomodulation in Women With Stress Urinary Incontinence N/A
Completed NCT05751213 - Knack Technique in Post-menopausal Women With Stress Urinary Incontinence N/A
Completed NCT04912830 - Tension Free Vaginal Tape Surgery - Follow up After 10 and 20 Years
Completed NCT05154760 - Effectiveness of Video Conferencing in Urinary Incontinence N/A
Completed NCT04643353 - Use of Non-ablative Vaginal Erbium YAG Laser for the Treatment of Stress Urinary Incontinence. N/A
Completed NCT03763097 - Sonographic Evaluation of the Single-incision Needleless (Contasure-needleless®) Mini-sling Placement to Predict Success
Recruiting NCT03650244 - Nationwide Observation Study to Evaluate the Efficacy and Tolerance of the Adjustable Medical Device REMEEX® in the Treatment of Male Stress Urinary Incontinence
Not yet recruiting NCT06109623 - Correlation Between Changes in Sex Hormone Levels and Stress Urinary Incontinence in Women
Active, not recruiting NCT05390970 - Platelet-Rich Plasma for Stress Urinary Incontinence N/A
Completed NCT03703843 - ARTUS MONO Artificial Urinary Sphincter N/A
Completed NCT05527639 - Kegel Exercises Prior to Strength Training to Improvestress Urinary Incontinence N/A
Completed NCT02407145 - Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women
Completed NCT04433715 - Identification of the UDI-6 and the IIQ-7 Cutoff Scores in Urinary Incontinent Women
Completed NCT05529238 - Kegel Exercises for Stress Urinary Incontinence N/A
Completed NCT05721807 - Physiotherapy in Stress Urinary Incontinence N/A
Not yet recruiting NCT06369922 - TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. N/A
Completed NCT05702567 - The Effectiveness of Transvaginal Radiofrequency in Women With Stress Urinary Incontinence N/A